Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has been effective diligently but unsuccessfully to create an one-time therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in phrases of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be used is an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as a combination therapy in the therapy of multi-drug-resistant HIV have been closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my last few shares. My first CytoDyn post, “CytoDyn: What In order to Do When It is Too Good To Be True?”, set away all of the following prediction:

Instead I expect it to become a serial disappointer. CEO Pourhassan presented such a very promotional image in the Uptick Newswire interview that I came away with a bad viewpoint of the business.

Irony of irony, my poor impression of the business has grown steadily, though the disappointment hasn’t been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > 6 bagger at the moment still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much storied treatment (which I shall relate to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the therapy and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s payment of $3.5 huge number of transfers ownership of the technology as well as linked intellectual property coming from Progenics to CytoDyn, and roughly 25 million mg of bulk drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 huge number of) as well as the first new drug program approval ($five million), and even royalty payments of five % of net sales upon commercialization.

Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many therapies and numerous indications, it has this individual treatment and a “broad pipeline of indications” because it puts it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a likely beneficial therapy in dozens of indications.

Its opening banner on the website of its (below) shows an active organization with diverse interests albeit centered on leronlimab, multiple disease types, multiple publications in addition to multiple delivering presentations.

Could all of it be smoke cigarettes and mirrors? That is a question I’ve been asking myself from the really start of my interest in this business. Judging by the multiples of thousands of several commentary on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m far from alone in this particular question.

CytoDyn is a traditional battleground, or even some may say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *